195 related articles for article (PubMed ID: 31743393)
1. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.
Grieve S; Wajnberg G; Lees M; Chacko S; Weir J; Crapoulet N; Reiman T
Blood Adv; 2019 Nov; 3(22):3613-3625. PubMed ID: 31743393
[TBL] [Abstract][Full Text] [Related]
2. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
3. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN; Abdi J; Yang Y; Chang H
Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
[TBL] [Abstract][Full Text] [Related]
5. MST1 downregulates TAZ tumor suppressor protein in multiple myeloma and is a potential therapeutic target.
Abegunde SO; Grieve S; Alfarra H; Reiman T
Exp Hematol; 2023 Jul; 123():34-45. PubMed ID: 37137439
[TBL] [Abstract][Full Text] [Related]
6. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
8. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
9. TAZ upregulates MIR-224 to inhibit oxidative stress response in multiple myeloma.
Abegunde SO; Grieve S; Reiman T
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1879. PubMed ID: 37539777
[TBL] [Abstract][Full Text] [Related]
10. Addiction to c-MYC in multiple myeloma.
Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
[TBL] [Abstract][Full Text] [Related]
11. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
12. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
13. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
14. The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2019 Apr; 10(4):324. PubMed ID: 30975979
[TBL] [Abstract][Full Text] [Related]
15. Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma.
Ye T; Mishra AK; Banday S; Li R; Hu K; Coleman MM; Shan Y; Chowdhury SR; Zhou L; Pak ML; Simone TM; Malonia SK; Zhu LJ; Kelliher MA; Green MR
Cell Rep; 2024 May; 43(5):114211. PubMed ID: 38722741
[TBL] [Abstract][Full Text] [Related]
16. The role of transcriptional coactivator TAZ in gliomas.
Li W; Dong S; Wei W; Wang G; Zhang A; Pu P; Jia Z
Oncotarget; 2016 Dec; 7(50):82686-82699. PubMed ID: 27764783
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
18. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2015 Sep; 6(26):22698-705. PubMed ID: 26087190
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.
Cottini F; Hideshima T; Suzuki R; Tai YT; Bianchini G; Richardson PG; Anderson KC; Tonon G
Cancer Discov; 2015 Sep; 5(9):972-87. PubMed ID: 26080835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]